There is an opportunity for the nutraceutical industry to leverage the pharmaceutical 26 industry's progress in oral drug delivery. The use of delivery approaches using formulation 27 with excipients or substances with a history of use in man has potential to improve solubility, 28 stability, or permeability of nutraceuticals, leading to improved oral bioavailability. 29
Introduction 35
With growing prevalence of lifestyle-associated diseases, including obesity, Type II diabetes 36 and cardiovascular disease, there is a need to reduce risks of onset of these diseases (Menotti 37 & Puddu, 2015) . Nutraceuticals are defined as isolated food-derived bioactive molecules, 38 which provide physiological benefits beyond basic nutrition (Pan, Lai, Dushenkov, & Ho, 39 2009 ). Recently, research has focused on such bioactives with anti-oxidative, anti-40 inflammatory, anti-hyperlipidemic and anti-hypertensive activities. However, there are many 41 hurdles to overcome for the oral delivery of nutraceuticals depending on the bioactive's 42 physicochemical properties. The molecule may be prone to sub-optimal release and 43 dispersion from the delivery dosage form and/or low solubility in small intestinal fluids 44 (bioacessibility), pH-and enzymatic degradation, biotransformation during gastrointestinal 45 transit, poor diffusion across mucus and low intestinal epithelial permeability; all of which 46 must be overcome prior to absorption into the bloodstream (Braithwaite, et al., 2014; 47 McClements, Decker, Park, & Weiss, 2009). Without appropriate delivery systems, current 48 nutraceuticals with such characteristics are unlikely to provide the intended physiological 49 effect, despite marketing claims to the contrary. 50
The pharmaceutical industry has examined microbes and plants as sources of drug discovery 51 molecules, examples being penicillin (Penicillium species), colchicine (autumn crocus), 52 acetyl salicylic acid (willow tree bark), and paclitaxel (pacific yew tree) (Dias, Urban, & 53 Roessner, 2012). There is now additional focus on food as a new source of bioactives. With 54 the growing consumer market for nutraceuticals, there is scope for the nutraceutical industry 55 to leverage innovative research from the pharmaceutical industry in delivering poorly soluble 56 and poorly absorbed molecules. These particular nutraceuticals may assist with reducing the 57 risks of certain diseases before pharmaceutical intervention is required, but without 58 appropriate oral formulation they will have limited efficacy. 59
Innovative strategies are being attempted by the pharmaceutical industry for oral delivery of 60 peptides including insulin, octreotide, salmon calcitonin (sCT) and parathyroid hormone 61 (PTH). Approaches include entrapment in protective delivery vehicles, strategies for 62 enhanced mucus penetration and epithelial permeation, as well as incorporation of excipients 63 as protease enzyme inhibitors (Maher, Duffy, Ryan, & Brayden, 2014) . Chemical 64 modification by a prodrug approach has been successful in improving small molecule oral 65 bioavailability. For example, the anti-viral prodrug, valacyclovir is converted to acyclovir in 66 eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in the body is inefficient and 98 supplementation is often required (Deckelbaum & Torrejon, 2012) . Although cod liver oil has 99 been an established source of EPA and DHA , there is interest in sustainable alternatives 100 including krill oil, flax-seed and walnut oil (Adarme-Vega, Thomas-Hall, & Schenk, 2014) . 101 EPA and DHA enhance production of anti-inflammatory lipid mediators, decrease production 102 of pro-inflammatory cytokines and decrease serum C-reactive protein, a clinical marker of 103 inflammation (Skulas-Ray, 2015). Supplementation with omega-3 fatty acids has anti-104 hyperlipidemic activity, reducing LDL-cholesterol and triglycerides (Maki, 105 Dicklin, Schild, & Geohas, 2014). Futhermore, Amarin Corporation's (Dublin, Ireland) 106
Vascepa® icosapent ethyl (eicosapentaenoic acid ethyl ester) is an FDA-approved 107 prescription medication for hypertriglyceridemia and there are plans to achieve a wider label 108 for use in patients with moderately elevated triglyceride levels (Braeckman, Stirtan, & Soni, 109 2015) . 110
Delivery of omega-3 fatty acids is difficult due to low aqueous solubility in the small 111 intestine and oxidative instability. Unsaturated fatty acids are prone to lipid oxidation, which 112 is accelerated by exposure to air, light and heat, resulting in a loss in functionality and leading 113 to off-flavour (Arab-Tehrany, et al., 2012). Upon reaching the small intestine, the fatty acids 114 need to be liberated from the delivery matrix, often an oil capsule, to allow incorporation into 115 mixed micelles, which seem to permeate the mucus layer and intestinal epithelia (Walker, 116 Decker, & McClements, 2015) . Delivery platforms are required to reduce lipid oxidation, 117 improve solubility and overcome poor mucus penetration. 118
Bioactive peptides 119
Proteins from food undergo enzymatic hydrolysis by digestive enzymes thereby releasing 120 smaller peptides, which have bioactive properties if they can be absorbed. Some peptides 121 inhibit angiotensin-converting enzyme (ACE), which can help maintain normal blood 122 pressure and prevent escalation of hypertension by subverting the renin-angiotensin-123 aldosterone system (Turpeinen, Jarvenpaa, Kautiainen, Korpela, & Vapaatalo, 2013) . Two 124 such tripeptides have been focussed on: Ile-Pro-Pro (IPP) and Val-Pro-Pro (VPP), both 125 isolated from milk β-casein ( Fig. 1) following fermentation by Lactobacillus helveticus 126 (Nakamura, et al., 1995) . Other derived antihypertensive peptides include Val-Tyr-Pro (VYP, 127 rice protein) , Gly-Leu-Pro (GLP, chum salmon skin) (Lee, Jeon, & 128 Byun, 2014) and His-Leu-Phe-Gly-Pro-Pro-Gly-Lys-Lys-Asp-Pro-Val (HLFGPPGKKDPV, 129 Peptides are prone to pancreatic serine protease digestion by chymotrypsin, trypsin and 137 elastase into small fragments and then further digestion to single amino acids by intracellular 138 carboxypeptidases. Presence of Pro residues confers resistance to such enzymes (Gleeson, 139 Heade, Ryan, & Brayden, 2015) . Due to their hydrophilic nature and high molecular weight 140 however, peptides more than three residues long typically have low mucus penetration and 141 intestinal permeability, resulting in variable oral bioavailability (Renukuntla, Vadlapudi, 142 Patel, Boddu, & Mitra, 2013). Delivery strategies therefore need to protect bioactive peptides 143 from enzyme degradation and to enhance both mucus and intestinal permeability. 144
Micronutrients 145
Essential vitamins and minerals are required in small doses, with deficiencies leading to 146 rickets (vitamin D), scurvy (vitamin C), neural tube defects (vitamin B 9 ), hypothyroidism 147 (iodine), hypokalaemia (potassium), and Keshan's disease (selenium). A nutritionally-148 balanced diet will provide the required micronutrients to a healthy individual, however, there 149 are many conditions that can still benefit from micronutrient supplementation including 150 calcium for osteoporosis and iron for iron-deficient anaemia (Wallace, et al., 2015) . The 151 physiological role of micronutrients includes roles as co-enzymes for metabolic processes, 152 antioxidants to remove reactive oxygen species (ROS), modulation of gene transcription and 153 structural components. 154
Delivery of micronutrients are also limited by individual physicochemical characteristics, as 155 they may be susceptible to bioaccessibility, stability, solubility, and bioavailability issues. 156
Vitamins C and E are prone to oxidation during processing and delivery, while fat soluble 157 vitamins (A, D, E and K) may not be liberated from the delivery matrix due to excessive 158 lipophilicity. Micronutrient bioavailability is effected by multiple processes, for example, 159 vitamin E is easily oxidised and has poor solubility. Anti-nutrients are compounds that 160 interfere with the absorption of nutrients and limit their bioavailability. Calcium, iron and 161 zinc can be chelated and cleared by dietary anti-nutrient phytate, hence the benefit of adding 162 phytase to a micronutrient delivery system. Orally-delivered phytase can therefore improve 163 oral calcium absorption in a pig model ( Therefore, oral delivery of minerals, somewhat ironically, may benefit from being taken in 167 the absence of food. 168
Phytochemicals 169
"Phytochemicals" are a large group of plant-derived compounds ( Fig. 1) , which have been 170 studied for their potent antioxidant activity and potential anti-inflammatory and anti-171 hyperlipidemic activity. They include phytosterols (e.g. plant stanol esters); organosulfers 172 (e.g. allicin from garlic); terpenoids (e.g. lycopene carotenoid from tomatoes) and 173 sesquiterpenes. Polyphenols are the largest class containing stilbenes (e.g. resveratrol from 174 grapes), isoflavones (e.g. genistein from soybean) and flavonoids-based agents (e.g. 175 kaempferol and naringenin from spinach and grapefruit respectively) (Gonzalez-Castejon & 176
Rodriguez-Casado, 2011). The anti-inflammatory mechanism of action of polyphenols 177 involves modulation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-178 κB), inhibition of Mitogen-activated protein kinases (MAPK) cascade, activation of nuclear 179 factor erythroid 2-related factor 2 (Nrf2), and reduction in pro-inflammatory cytokines, all of 180 which are relevant in treatment of IBD (Martin & Bolling, 2015) . Resveratrol improved 181 expression of the cytoprotective NAD(P)H dehydrogenase, quinone 1 (NQO1), in cancer 182 patients dosed with [ 14 C]-resveratrol (Cai, et al., 2015) . 183
There are a multitude of factors affecting oral bioavailability of phytochemicals due to their 184 unique physicochemical properties. For example, kaempferol has poor water solubility and 185 favours alkaline pH conditions, resulting in low oral bioavailability (2%) in a rat model 186 (Barve, et al., 2009) . It is also prone to biotransformation by Phase I oxidative metabolism 187 and Phase II glucuronidation in intestinal epithelia (Barve, et al., 2009) . Resveratrol is readily 188 soluble in ethanol, however, it has poor water solubility and is easily photo-isomerised and 189 metabolised by glucuronidation (Patel, et al., 2011) . Oral delivery approaches for 190 phytochemicals need to overcome solubility issues, provide a dose sufficient to overcome 191 partial metabolism, and boost epithelial permeability. It is important to note however, that 192 assumptions of straight-forward pharmacological dose-response concepts being applied to 193 phytochemicals has been challenged by Cai et al., who demonstrated a non-linear dose 194 response for the chemoprotective effects of resveratrol in humans and mice (Cai, et al., 2015), 195 with efficacy seen at the low doses found in food, but not at high doses. 196
Bioaccessibility and solubility in GIT 197
Solubility is one of the first hurdles which must be overcome in oral delivery of bioactive 198 molecules. The Food and Drug Administration (FDA) adopted the Biopharmaceutics 199 NuBACS introduces the concept of "bioaccessibility", the ability of the bioactive compound 212 to be accessible to the body for absorption from the delivery matrix. Bioaccessiblity, 213 absorption and transformation of nutraceuticals are features of the NuBACS, and this is 214 relevant for functional foods. In contrast, oral delivery of pharmaceutical agents is achieved 215 by capsules, tablets or suspensions and is governed by the BCS specifically in terms of 216 solubility and permeability. Although some nutraceuticals may require liberation from a 217 functional food or whole food, the focus here is on delivery strategies for isolated 218 nutraceutical bioactives, therefore, liberation refers to release from a delivery vehicle or 219 formulation prior to solubilisation. Solubility is however, a major hurdle for certain 220 nutraceuticals, particularly fatty acids and phytochemicals. Therefore, the lipophilic molecules, EPA, DHA, resveratrol, and kaempferol may pass 251 through mucus in association with luminal-derived moieties. Nanoparticles coated with small 252 hydrophilic polymers including low molecular weight high density polyethylene glycol 253 (PEG) and polysialic acid, can slip through the mesh of mucus potentially allowing for 254 release of nutraceutical at intestinal epithelia or uptake of nutraceutical-entrapped 255 nanoparticles (Ensign, et al., 2013) . 256
Upon diffusion through the mucus, there are several routes which a bioactive agent may 257 permeate the intestinal epithelia. Transport via the paracellular route requires movement 258 through tight junctions. A molecular radius between 10-50 Å and molecular weight <500 Da 259 is required and the bioactive must be hydrophilic in nature (Larregieu & Benet, 2014) . 260
Paracellular transport reduces risk of intracellular metabolism, which is relevant for 261 phytochemicals and bioactive peptides. Transcellular transport involves molecules passing 262 across the apical membrane by passive diffusion, receptor mediation or endocytosis. 263
Hydrophobic molecules can pass across the phospholipid bilayer by passive diffusion. 264
According to Fick's law of diffusion molecules with a relatively high oil-water partition 265 coefficient (K ow ) or greater hydrophobicity (log P) can pass the cell membrane more 266 efficiently (e.g. β-carotene, log P =15.2) compared to molecules with lower values (e.g. IPP, 267 log P= 1.07; vitamin C, log P= 2.77) . There is a balance required, 268 as the greater the log P the less the solubility: a log P of < 2.5 may be optimal, however, this 269 depends on the formulation or presence of bile salts and surfactants, which may assist in 270 solubilising lipophilic nutraceuticals and presenting them as components of mixed micelles. 271
The epithelium of the small and large intestine has a multitude of transporters localised on the 272 apical membrane which have roles in uptake of nutrients and absorption of drugs. These 273 membrane bound proteins are relevant to the uptake of many nutraceuticals. Fatty acids are 274 transported by intestinal fatty acid-binding proteins (I-FABP), and bioactive di-and 275 tripeptides are carried by the proton coupled peptide transporter (PEPT1). Calcium uptake is 276 mediated by the vitamin D receptor, while vitamin C is carried on the sodium-vitamin C co-277 transporter (SVCT) (Lin, Yee, Kim, & Giacomini, 2015). In the case of IPP at least two 278 uptake pathways are likely to play a role: the paracellular route due to its low molecular 279 weight (MW) and the transcellular route due to its interaction with the PEPT1 carrier. 280 Appropriate exploitation of one or both of these intestinal permeation routes may enhance 281 absorption of these types of molecules. 282
Food-based strategies for improving oral delivery of nutraceuticals 283
Delivery vehicles 284 A delivery vehicle can control delivery and release of the nutraceutical. The use of delivery 285 vehicles in the pharmaceutical industry has been investigated for oral delivery of antibiotics, 286 vaccines, cancer therapeutics and biopharmaceuticals Ryan, et al., 287 2013 ). Due to the hurdles which must be overcome to orally deliver a therapeutically effect 288 dose of a nutraceutical, delivery vehicles are of increasing interest. In particular the utilisation 289 of food grade ingredients with GRAS (generally regarded as safe) status to create the delivery 290 vehicle is a promising area of current research. Furthermore, nutraceutical loaded in 291 pharmaceutical grade delivery vehicle formulations has also emerged in recent years. 292
Lipid and surfactant based systems 293
Liposomes or nanoliposomes are formed when phospholipids self-assemble into a lipid 294 bilayer due to hydrophobic interactions with the fatty acid chain. Niosomes are formed when 295 non-ionic surfactants assemble into similar structures (Fig. 3) . Cholesterol is often added to 296 the formulation as it increases rigidity strength of the membrane and confers steric stability. There are some characteristic differences between liposomes and niosomes, particularly the 301 oxidative stability of the particles dye to phospholipid oxidative degradation. They are both 302 suitable for loading of lipophilic nutraceuticals in the inner core of the bilayer membrane, as 303 well as hydrophilic compounds in the aqueous core. 304
The carotenoid class of phytochemicals show strong anti-oxidative potential, however, they 305 are highly hydrophobic (log P >13), which makes them suitable candidates for liposome 306 formulation. Lutein was found to be most easily incorporated from a series of carotenoids 307 with the rank order lutein > β-carotene > lycopene > canthaxanthin (Xia, et al., 2015) . In vitro 308 release showed lycopene and canthaxanthin exhibited a burst release from liposomes whereas 309 lutein and β-carotene displayed a sustained release (Tan, et al., 2014) . Curcumin is another 310 lipophilic phytochemical with anticancer and antimalarial activity, which can be incorporated 311 into liposomes (Shin, et al., 2013) . Curcumin was soluble upon in vitro lipolysis, and 312 permeation across Caco-2 monolayers was enhanced compared to free curcumin (Memvanga, 313 Coco, & Préat, 2013). When delivered in combination with β-arteether (an antimalarial drug), 314 curcumin loaded liposomes increased survival rate in rodents compared to β-arteether or 315 curcumin alone, thereby showing potential of the liposome formulation. 316
Due to their structure, liposomes and niosomes have the potential for co-encapsulation. One to reduce lipid hydroperoxide production of soybean oil emulsions (Uluata, McClements, & 342 Decker, 2015). The size of the lipid droplet effects epithelial cellular uptake of flavonoid 343 loaded nanoemulsions in HCT116 cells, with 67 nm and 125 nm showing 4-fold higher 344 uptake compared to 203 nm . Coenzyme Q 10 (CoQ 10 ) is a powerful 345 antioxidant which is highly hydrophobic and is also required for healthy mitochondrial 346 function. CoQ 10 formulated into a salmon oil-salmon lecithin nanoemulsion had a 10-fold 347 increase in plasma concentration compared to water vehicle after oral gavage in Wistar rat 348 ( Fig. 4) (Belhaj, et al., 2012) . Tangeretin, a citrus flavone, has shown potential as an 349 anticancer agent when formulated into a nanoemulsion it improved in vitro tumour 350 suppression and reduced incidence of colonic adenomas compared to control in the 351 azoxymethan/dextran sodium sulphate (AOM/DSS)-induced colitis mouse model (Ting, 352 Chiou, Pan, Ho, & Huang, 2015) . 
Biopolymer based systems 374
Polyelectrolyte complexes (PECs) are formed by electrostatic interaction between oppositely 375 charged biopolymers e.g. iota carrageenan and protamine (Fig. 3) . Entrapped PECs are 376 formed by solubilising nutraceuticals in either the positively or negatively charged 377 biopolymer, and then the opposite charged biopolymer is mixed in. PECs formed between 378 cationic gelatin and gum Arabic swelled and aggregated at pH 4.5, whereas they were stable 379 between pH 5.5 -7.5 and had diameters of 110 -160 nm (Sarika, Pavithran, & James, 2015) . 380
These PECs may be promising carriers for nutraceuticals, however the swelling at lower pH 381 poses issues at gastric pH values. 382 GRAS food biopolymers are an abundant source for polyelectrolyte complexation e.g. 383 amylose, starch, pectin, carrageenan and chitosan. Resveratrol complexed in a gelatin PEC 384 showed improved anti-proliferative efficacy than free resveratrol and improved 385 bioavailability in mice compared to free resveratrol solution after intravenous injection 386 (Karthikeyan, Rajendra Prasad, Ganamani, & Balamurugan, 2013). PECs are a class of 387 nanoparticles which are not well exploited for nutraceuticals to date with limited in vivo data; 388 on the other hand they have shown promise for therapeutic peptides. For example, insulin and 389 sCT display improved stability when complexed in PECs (Lu, et al., 2012; Ryan, et al., 390 2013) . 391
Hydrogels are a 3D polymer network with an extremely high abundance of water, which 392 when appropriately cross-linked can form hydrogel particles in the nano-sized range (Fig. 3) . 393
These can be formed from protein gelation via physical, chemical or biochemical methods 394 which self-crosslink between denatured proteins, whereas, carbohydrate based hydrogels 395 generally require addition of an ionic cross-linker. They may be composed of GRAS 396 biopolymers including pectin, alginate, carrageenans, agar, chitosan, gelatin, whey protein, 397 caseins, soy protein. Hydrogel particles can also contain dispersed oil droplets for carrying 398 lipophilic molecules. When β-carotene was formulated into each of a conventional emulsion, 399 a hydrogel, and an oil dispersion-"filled" hydrogel, the latter had an improved release of the 400 bioactive compared to both formulations due to solubilising effect and increased lipid surface 401 area (Mun, Kim, & McClements, 2015) . 402
Comprehensive preclinical in vivo studies of oral delivery of hydrogel particles with 403 nutraceutical bioactives are lacking similar to PECs, providing an area of under-exploited 404 delivery vehicles. However, one rodent study suggested that Nile Red-loaded conventional 405 emulsions had superior oral bioavailability compared to lipid-entrapped hydrogels (Li, Kim, 406 Park, & McClements, 2012) . Caveats were that the diameters of particles were not 407 comparable (0.36 µm vs. 510 µm respectively) and the loading of a nutraceutical may yield 408 different results compared to Nile Red. Insulin has been delivered orally in vivo in hydrogels 409 in rodents, but there are major issue in how to translate such formulations from rodent models 410 to clinical trials (Déat-Lainé, et al., 2013). Hydrogel particles formulated from whey protein 411 and alginate were loaded with insulin and yielded ̴ 2.4% relative bioavailability after intra-412 duodenal instillation in a rat model. Polyacrylic acid-derived hydrogels were cross-linked 413 with poly( L -glutamic acid) and then loaded with insulin (60 IU/kg); this formulation resulted 414 in a 33% reduction of plasma glucose levels in the streptozotocin (STZ)-induced rat Type 1 415 diabetes model (Gao, He, Xiao, Zhuang, & Chen, 2013 ). Finally, insulin was also loaded into 416 lectin-functionalized and ionically-gelated carboxymethylated kappa-carrageenan particulates 417 and induced 14% relative bioavailability by the oral route compared to subcutaneous 418 injection in rats (Leong, et al., 2011) . 419
Protein-carbohydrates (self-assembly structures) are formed from interaction between 420 anionic polysaccharides and cationic protein surface groups, similar to PECs. Alternatively, 421 they may be formed by thermal denaturation or aggregation of a globular protein followed by 422 addition of an ionic polysaccharide, while still relying in part on electrostatic charge (Fig. 3) . Curcumin was complexed into chitosan-zein particulates, improved thermal and UV stability 431 and anti-oxidative scavenging capacity was retained (Liang, et al., 2015) . Similarly, when 432 curcumin was complexed in a carboxymethyl chitosan-kafirin (a prolamin protein from 433 sorghum) particulates, it again improved UV stability and improved cellular uptake in Caco-2 434 (Xiao, Nian, & Huang, 2015) . EGCG is an abundant polyphenol from green tea and a potent 435 antioxidant; it had a burst release profile and retained cytotoxicity against cancer cell lines in 436 vitro when complexed in a chitosan-caseinophosphopeptide particulate (Hu, Xie, Zhang, & 437 Zeng, 2014). Furthermore, EGCG complexed in ovalbumin-dextran, saw a small increase in 438 permeability across Caco-2 monolayers compared to free EGCG (Li & Gu, 2014) . 439
Resveratrol complexed in a zein-based nanoparticle improved oral bioavailability 19-fold 440 compared to resveratrol solution (Error! Reference source not found.) and reduced serum 441 TNF-α (15%) against control in a mouse model of endotoxic shock (Penalva, et al., 2015) . 442
Intestinal Absorption Improvements

443
Although delivery vehicles increase permeability in vitro and in vivo animal models, there is 444 still potential to further increase the intestinal permeability. Intestinal permeation enhancers 445 (PEs) have been researched for oral delivery of hydrophilic peptide drugs in the last two 446 decades . Improving nutraceutical absorption can be achieved in two 447 ways (Fig. 6) ; improve mucodiffusion of lipophilic agents (e.g. omega-3 fatty acids and 448 phytochemicals) using mucolytics; improve paracellular and transcellular permeability of 449 bioactive peptides, micronutrients and hydrophilic phytochemicals using PEs. 450
Mucolytics 451
Mucus diffusion enhancers such as N-acetylcysteine (NAC), bromelain, and papain hold 452 potential for nutraceuticals affected by inability to penetrate the small intestinal mucus layer. 453
Papain is a mucolytic protease found in papaya; when decorated on nanoparticles, it 454 improved permeation and reduced mucus viscosity in vitro (Müller, et al., 2012) . Bromelain, 455 a pineapple stem mucolytic enzyme, was formulated on the surface of nanoparticles and 456 compared against papain for in vitro mucus permeation resulting in enhanced penetration: 457 bromelain > papain > conventional nanoparticles (Pereira de Sousa, et al., 2015). Papain 458 decorated nanoparticles were also shown to penetrate into deeper mucus layers, when 459 delivered by oral gavage in a rat model, with higher retention within the jejunum (Müller, 460 Perera, König, & Bernkop-Schnürch, 2014). This is of particular interest, as the jejunum is 461 the main target for nutraceutical bioactive absorption. 462 NAC is an antioxidant nutritional supplement and it is also used as a mucolytic agent by 463 breaking disulphide bonds (Yuan, et al., 2015) . When an intestinal PE, tetradecyl maltoside 464 (TDM) was tested on Caco-2-and mucus-producing HT29-MTX-E12 monolayers, it was 465 shown that NAC-pre-treatment on E12 monolayers resulted in comparable apparent 466 permeability (P app ) values of salmon calcitonin across Caco-2 and E12 (Petersen, Nielsen, 467 Rahbek, Guldbrandt, & Brayden, 2013). The blood serum levels of fluorescein 468 isothiocyanate-dextran MW 4000 (FD-4, a fluorescent marker molecule for the paracellular 469 route) was improved 2.8-fold upon intra-jejunal administration of NAC (5% w/v) in rats, and 470 showed a mucolytic effect up to 60 minutes (Takatsuka, Kitazawa, Morita, Horikiri, & 471 Yoshino, 2006) . 472
The application of mucolytic agents also holds promise for lipophilic nutraceuticals, which 473 interact with glycoproteins and lipids in mucus (Sigurdsson, et al., 2013) . This interaction 474 reduces the likelihood of epithelial permeation as mucus is continuously turned over and 475 would result in the bioactive being washed away. Whereas mucolytics reduce this risk of this 476 occurring by enhancing mucus penetration. Mucolytics are most often investigated in the 477 context of airway mucus in cystic fibrosis, where NAC is used at high concentrations. 478
Recently a synthetic thiol-carbohydrate (methyl 6-thio-6deoxy-α-D-galactopyranoside) was 479 found to be a more potent mucolytic (Yuan, et al., 2015) . Co-administration of lipophilic 480 nutraceuticals and mucolytics in the context of an enteric coated oral dosage form may 481 therefore control release in the small intestine, improve mucus penetration and improve 482 absorption. 483
Intestinal Permeation Enhancers (PEs) 484
PEs can increase oral bioavailability assuming that the nutraceutical can also survive liver 485 first pass metabolism. Of these, the medium chain fatty acid (MCFS) sodium caprate (C 10 ) is 486 well established as a food additive and was a component of an antibiotic suppository once 487 marketed in Sweden and Japan (Maher, et al., 2014) . Ideally, PEs should be 488 pharmacologically inert, have excipient or Generally-Regarded-As-Safe (GRAS) status, and 489 have a history of use in man. PEs are often used for peptide oral delivery with candidates 490 including sCT, insulin, glucagon-like Peptide 1 (GLP-1) analogues, and octreotide. For 491 example, The technology of Enteris Biopharma (New Jersey, USA) is currently in Phase II 492 with a PE (an acyl carnitine), a peptidase inhibitor (citric acid) and parathyroid hormone 493 (Stern, Mehta, & Carl, 2013) . The technology of Chiasma (Jerusalem, Israel) recently 494 completed Phase III for oral octreotide and it comprises a PE (caprylic acid) in a water-in-oil 495 suspension (Tuvia, et al., 2012) . Merrion Pharmaceuticals (Dublin, Ireland) uses a 496 gastrointestinal permeation enhancement technology (GIPET™) built around the PE (C 10 ) in 497 matrix tablets and it completed an oral Phase I study with GLP-1 (Karsdal, et al., 2015) . 498
Finally, the technology of Oramed (Jerusalem, Israel) is has reached Phase IIb for oral insulin 499 and it comprises a PE (EDTA) and soy-bean trypsin inhibitor (Lewis & Richard, 2015) . 500 MCFA-based PEs act by re-organising proteins at the epithelial tight junction (Fig. 6) , (e.g. 501 tricellulin and claudin 5), and by mild detergent fluidizing effect on the plasma membrane 502 (Brayden, Gleeson, & Walsh, 2014; Krug, et al., 2013) . This allows for poorly permeable 503 molecules to either transiently permeate across tight junctions, or possibly to be entrapped in 504 mixed micelles with capacity to cross lipid bilayers. PEs generally cause a reduction of 505 transepithelial electrical resistance (TEER) using in vitro and ex vivo intestinal epithelial 506 models. This reduction suggests an opening of tight junctions or perturbation of the epithelia. 507
They have shown significant increase in apparent permeability of [ 14 C]-mannitol (a marker 508 for paracellular transport) and FD-4 across isolated intestinal mucosa on the Ussing chamber 509 model. For example, C 10 showed an increase in FD-4 permeability in Caco-2 monolayers, an 510 8-fold increase across isolated colonic mucosa and a 2-fold increase in colonic instillations in 511 vivo . This effect is also associated with a temporary perturbation of 512 the intestinal epithelia. However this mild damage induced by MCFA such as C 10 is quickly 513 repaired, which was shown after in situ intestinal injections in rats (Wang, Maher, & 514 Brayden, 2010) . The continuing progress of C 10 and other PEs in clinical trials for oral 515 peptides is also addressing safety aspects that may be associated with increased oral 516 bioavailability. 517
Many of these PEs are commonly used in food processing with GRAS status or are of food 518 origin. Candidates PEs include coco-glucosides (CG), chitosan derivatives, bromelain, 519 EDTA, oleic acid, alkyl maltosides, medium chain fatty acids (MCFA) and sucrose esters 520 (Aguirre, et al., 2014; Szűts & Szabó-Révész, 2012) . Furthermore, many isolated food 521 components can modulate tight junction integrity in vitro by enhancing permeability by 522 opening tight junctions. Although many of these PEs work especially well in the colon, the 523 target site for absorption of nutraceuticals is predominantly the jejunum. The capacity for 524 enhancement was tested in different regions of the rat intestine with C 10 and insulin using an 525 in situ loop model, which showed a rank order of plasma glucose reduction: colon > ileum > 526 jejunum >duodenum (Morishita, Morishita, Takayama, Machida, & Nagai, 1993). The apical 527 membrane of the small intestine is often exposed to bile salts and fatty acids resulting in 528 resistance to surfactant perturbation compared to colon. TEER decreased in isolated rat 529 jejunum and ileum using TDM and CG, however, there was no increase in the permeability 530 of FD-4. This lack of effect from these PEs may be due to the marker MW of 4kDa, because 531 when HT-29/B6 monolayers were treated with C 10 , a 3-fold increase in fluorescein (330Da) 532 was detected (Krug, et al., 2013) . Isolated rat jejunum was treated with C 10 and sodium salt of 533 10-undecylenic acid (uC 11 , an antifungal agent), a 1.4-3.6-fold increase was shown for FITC-534 labelled IPP (714 Da) and LKP (745 Da) Gleeson, et al., 2015) . 535 Therefore, using the appropriate PE in the jejunum holds the potential to improve the 536 permeability of nutraceuticals and potentially improve oral bioavailability. On the other hand, 537 kaempferol, curcumin and daidzein may have potential for useful application in inflammatory 538 bowel disease (Kosińska & Andlauer, 2013) , where they can repair membranes and reduce 539 abnormally high epithelial permeability. 540
Conclusions 541
Nutraceuticals offer the opportunity to prevent onset and escalation of lifestyle-associated 542 diseases due to their range anti-oxidative, anti-inflammatory, anti-hyperlipidemic and 543 antihypertensive activities. Progress has been made in adopting Pharma oral delivery 544 strategies to improve solubility, stability and permeability of nutraceutical bioactives. In 545 particular, solubilisation technologies can overcome issues associated with the delivery of 546 hydrophobic compounds (e.g. resveratrol and curcumin) using lipid-based systems. There has 547 often been too much emphasis put on the in vitro assays suggesting anti-oxidative, anti-548 inflammatory and anti-hypertensive actions of nutraceuticals. One of the main issues is that 549 many nutraceuticals are not tested in in vivo preclinical studies, it is therefore impossible to 550 assess whether they are predictive of efficacy. However, at least some nutraceuticals can be 551 efficiently formulated and show promising data in rodent models (Dhule, et Absorption enhancement is an area yet to be used for improving oral nutraceutical delivery. 566
Mucolytics and PEs hold potential to improve absorption of both lipophilic and hydrophilic 567 nutraceuticals, particularly as many of these are food-grade and/or food additives. However, 568 there is a question regarding the safety of PEs due to perturbation of the intestinal epithelia 569 through mild detergent-based surfactant effects, even for agents with GRAS status or with a 570 history of use in man (Chassaing, et al., 2015) . Although toxicity of various PEs under acute 571 dosing regimens has not been found in clinical trials for oral peptides to date (Melmed, et Fatty acids (eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)), bioactive 939 peptides (Ile-Pro-Pro (IPP), and Leu-Lys-Pro, (LKP)), micronutrients (Vitamins B6, C and 940 D3) and phytochemicals (the remainder). Adapted with permission (Pan, et al., 2009 ). 941 resveratrol suspension (▲) in an endotoxic shock mouse model. The dose was 15 mg/kg and 958 resveratrol plasma AUC was 5.17 > 0.60 > ND respectively. Adapted with permission 959 (Penalva, et al., 2015) . 960 Nanoemulsions Surfactant and oil Essential oils (Gulotta, Saberi, Essential oils (Gulotta, et al., 
